Analyst Ratings For Loxo Oncology (NASDAQ:LOXO)
Today, Stifel Nicolaus reiterated its Buy rating on Loxo Oncology (NASDAQ:LOXO) with a price target of $135.00.
Some recent analyst ratings include
- 3/2/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 3/1/2018-Cann Reiterated Rating of Buy.
- 2/22/2018-CIBC initiated coverage with a Outperform rating.
- 2/22/2018-Oppenheimer initiated coverage with a Outperform rating.
- 11/28/2017-William Blair initiated coverage with a Outperform rating.
- 11/14/2017-JMP Securities Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- On 2/13/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $96.57 per share and the total transaction amounting to $1,448,550.00.
- On 2/13/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $96.34 per share and the total transaction amounting to $296,919.88.
- On 2/12/2018 Jennifer Burstein, VP, sold 1,700 with an average share price of $93.24 per share and the total transaction amounting to $158,508.00.
- On 1/22/2018 Avi Z Naider, Director, sold 15,000 with an average share price of $100.00 per share and the total transaction amounting to $1,500,000.00.
- On 1/17/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $88.21 per share and the total transaction amounting to $1,323,150.00.
- On 1/17/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $88.21 per share and the total transaction amounting to $271,863.22.
- On 1/16/2018 Jennifer Burstein, VP, sold 1,500 with an average share price of $87.50 per share and the total transaction amounting to $131,250.00.
Recent Trading Activity for Loxo Oncology (NASDAQ:LOXO)
Shares of Loxo Oncology closed the previous trading session at 115.84 up +0.79 0.69% with 35218 shares trading hands.